Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of oral HDM201 in TP53 wild-type advanced solid and hematologic tumors
NL-OMON46915Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of siremadlin in Nonhematologic neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more (2 arms), sponsored by Novartis. Primary endpoint: Maximum tolerated dose and/or recommended dose for expansion. Started Oct 2014; status: active, not recruiting.
02
Drugs
siremadlin
03
Conditions
Nonhematologic neoplasmsacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON46915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46915.